TY - JOUR
T1 - The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer
AU - Borgmann, Kerstin
AU - Raabe, Annette
AU - Reuther, Sebastian
AU - Szymczak, Silke
AU - Schlomm, Thorsten
AU - Isbarn, Hendrik
AU - Gomolka, Maria
AU - Busjahn, Andreas
AU - Bonin, Michael
AU - Ziegler, Andreas
AU - Dikomey, Ekkehard
N1 - Funding Information:
The authors greatly acknowledge the technical assistance of Mrs. Alexandra Zielinski. This project was supported by Deutsches Bundesamt für Strahlenschutz with Grant No. StrSch4460 and in part (T.S.) also by Deutsches Bundesministerium für Bildung und Forschung in the framework of the program for medical genome research (FKZ:01GS08189).
PY - 2010/7
Y1 - 2010/7
N2 - Purpose: Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors. Materials and methods: The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay. Results: No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18-0.08, p = 0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p = 1.75 -9). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%. Conclusion: G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.
AB - Purpose: Comparing the chromosomal radiosensitivity of prostate cancer patients with that of healthy donors. Materials and methods: The study was performed on 81 prostate cancer patients characterised by a clinical stage of predominantly pT2c or pT3a and a median age of 67 years. As healthy donors 60 male monozygotic twin pairs were recruited with a median age of 28 years. Chromosomal radiosensitivity was measured using both G0- and G2-assay. Results: No difference between healthy donors and prostate cancer patients was detected concerning G0-radiosensitivity, since medians were similar (Hodges-Lehmann estimate: -0.05, 95% CI: -0.18-0.08, p = 0.4167). However, a pronounced difference was determined for G2-radiosensitivity with prostate cancer patients showing a significantly higher sensitivity compared to healthy donors (Hodges-Lehmann estimate: -0.41, 95% CI: -0.53 to -0.30, p = 1.75 -9). Using the 90% quantile of G2-radiosensitivity in healthy donors as a threshold for discrimination the fraction of prostate cancer patients with elevated radiosensitivity increased to 49%. Conclusion: G2-, but not G0-radiosensitivity is a promising marker for predisposition of prostate cancer.
UR - http://www.scopus.com/inward/record.url?scp=77953958454&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2010.04.018
DO - 10.1016/j.radonc.2010.04.018
M3 - Journal articles
C2 - 20452694
AN - SCOPUS:77953958454
SN - 0167-8140
VL - 96
SP - 19
EP - 24
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 1
ER -